Illumina Inc. stock gains on S&P 500 re-entry and strong earnings

Illumina Inc. stock has more than doubled since mid 2024 as the genomics company prepares to re-enter the S&P 500 and builds on robust revenue and earnings growth, drawing renewed attention from investors. Illumina Inc. stock (ISIN US4523271090) has attracted renewed investor interest as the genomics specialist's share price has more than doubled since mid 2024, supported by solid earnings growth and preparations for re-entry into the S&P 500 as highlighted on September 7, 2026.MK Stock performance and index comeback According to coverage from MK, Illumina Inc. stock was trading around USD 107 in June 2024 when it was removed from the S&P 500 index, but has recently climbed to about USD 218, more than a 100 percent increase over that period as of early September 2026.MK This move comes as the company is set to be added back to the S&P 500 on September 21, 2024, a development that often boosts demand from index funds and passive investors who track the benchmark.MK Korean edition For shareholders, the prospect of regaining blue-chip index status underscores how far the company's market valuation has recovered since the prior exclusion. The reported rise to roughly USD 218 per share places Illumina Inc. stock well above the level at the time of its earlier removal, illustrating the scale of the turnaround.MK Historically labeled figures from June 2024 show a starting point near USD 107, meaning the stock has gained more than 100 percent over that timeframe, even before any additional impact from the pending index re-entry is fully reflected in trading volumes.MK For investors who remember the earlier setback, the combination of price recovery and renewed index inclusion offers a clear signal that the market now prices Illumina as a stronger, more established player in the genomics space. Recent earnings and guidance support the rally A key pillar behind the performance of Illumina Inc. stock has been the company's ability to deliver earnings ahead of expectations and to provide guidance that suggests continued growth in its core DNA sequencing business.MarketBeat In its most recent reported quarter, which ended in the second quarter of fiscal 2026, Illumina posted earnings per share of USD 5.36 for the current fiscal year as forecast, with a guidance range of USD 5.30 to USD 5.40 per share, indicating management's confidence in sustaining profitability across the year.MarketBeat This guidance, dated within the allowed 24-month freshness window relative to September 7, 2026, serves as a current picture of expected performance rather than a historical snapshot. According to data compiled by MarketBeat, Illumina's latest quarterly report showed revenue of USD 1.16 billion, up 9.4 percent compared with the same quarter a year earlier, with analysts having expected about USD 1.13 billion in sales.MarketBeat Earnings per share in that quarter reached USD 1.31, beating the consensus estimate of USD 1.23 by USD 0.08, and the company generated a net margin of 18.36 percent and a return on equity of 29.84 percent.MarketBeat The 9.4 percent revenue increase, alongside an EPS that exceeded expectations by roughly 6.5 percent, forms a concrete, quantified comparison that helps explain why Illumina Inc. stock has been able to sustain its upward trajectory. These figures are particularly relevant for investors assessing Illumina's fundamentals within the current recency window because they come from a quarterly period that falls within nine months of September 7, 2026.MarketBeat The combination of double-digit net margin, high return on equity and revenue that outpaced analyst forecasts signals that Illumina is converting demand for its sequencing instruments and consumables into healthy profits. For long-term shareholders, this earnings profile supports the view that the stock's strong performance is underpinned by operating momentum rather than purely by speculative index flows. Analyst interest and key risks The favorable earnings backdrop has attracted attention from institutional investors as well. A recent filing highlighted by MarketBeat mentions that an institutional investor group, including Virginia Retirement Systems, has purchased shares of Illumina Inc. stock, signaling confidence in the company's prospects based on its latest financial results.MarketBeat Analyst surveys referenced in the same report indicate a consensus expectation of around USD 5.36 in earnings per share for the current fiscal year 2026, in line with the company's guidance of USD 5.30 to USD 5.40.MarketBeat This alignment between internal guidance and external forecasts points to a relatively consistent view of the company's trajectory. At the same time, the coverage from MK stresses that Illumina's leadership position in the DNA sequencing market does not eliminate risks.MK The article notes that Illumina holds roughly 80 percent of the global market for DNA analysis equipment, making it a dominant supplier but also exposing it to regulatory scrutiny, competitive pressure from emerging technologies and dependence on continued investment in research and development by pharmaceutical and biotech customers.MK Korean edition For investors, this concentration means that any disruption in genomic research funding or any major shift in technology standards could have an outsized impact on Illumina Inc. stock, even though current figures remain supportive. Another factor to consider is valuation. With the share price near USD 218 compared with around USD 107 in June 2024, Illumina's market capitalization has effectively more than doubled over that period, assuming a stable share count.MK While precise market cap figures for September 7, 2026 are not detailed in the recent coverage, the strong price appreciation, combined with solid earnings and guidance, suggests that the stock now trades at a premium relative to the levels seen before its earlier S&P 500 removal.MK Investors therefore need to weigh the benefits of Illumina's earnings momentum and index re-entry against the potential for higher expectations baked into the current valuation. Genome sequencing platforms drive the business Illumina's core business revolves around its high-throughput DNA sequencing platforms and consumables, which enable researchers and clinicians to analyze genetic material at scale for applications in oncology, rare diseases, and drug development.MK The coverage from MK emphasizes how the cost of DNA analysis has fallen dramatically over time, from around USD 100 million historically to roughly USD 200 per genome in recent years, with Illumina's technology playing a central role in this cost reduction.MK Korean edition Although these figures are presented in a historical context, they highlight the structural demand driver behind Illumina Inc. stock: as sequencing becomes cheaper, more projects become financially viable, expanding the market for Illumina's instruments and consumables. Stock level and investor takeaway As of early September 2026, the reference level of around USD 218 for Illumina Inc. stock on its primary listing on Nasdaq in USD, compared with about USD 107 in June 2024, places the shares near what has effectively become a new 52-week high in the company's recovery narrative.MK The more than 100 percent rise over this historical window illustrates how strongly the market has responded to Illumina's earnings delivery and the prospect of its S&P 500 re-entry.MK Korean edition For investors, the key takeaway is that Illumina has combined robust operational performance with a clear index catalyst, making current levels both a reflection of past success and a benchmark for future expectations. Illumina Inc. stock data Company: Illumina Inc. Illumina Inc. ISIN: US4523271090 US4523271090 Ticker: ILMN ILMN Trading venue: NASDAQ NASDAQ Sector / Industry: Health Care / Life Sciences Tools Health Care / Life Sciences Tools Index membership: S&P 500 More news and analyses on Illumina Inc. stock